<DOC>
	<DOCNO>NCT00252993</DOCNO>
	<brief_summary>This randomize , double blind , placebo control , multicenter study design ass safety efficacy DDP225 patient chronic functional vomiting . Male female patient 18 65 year age functional vomit history least 12 week precede 12 month cyclic vomit history least 3 episode previous 12 month eligible . A total 30 eligible patient chronic functional vomiting enrol . The total duration study participation individual patient approximately 15 week ( 105 day ) initial screen visit final study evaluation . The total duration dose study medication ( either DDP225 placebo ) 12 week . Patients satisfy inclusion criterion none exclusion criterion eligible enter Treatment Period randomly assign one three treatment group . After patient randomized enters Treatment Period , he/she take appropriate study medication day 84 day return clinic two week interval total six visit Treatment Period . During Treatment Period , patient maintain daily diary complete questionnaire . One week complete 84-day Treatment Period , patient return clinic final safety evaluation include physical examination , electrocardiogram , clinical laboratory testing .</brief_summary>
	<brief_title>12 Weeks Treatment With DDP225 Placebo Patients With Chronic Functional Vomiting</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<criteria>1 . Male female patient 18 65 year age , inclusive . 2 . History functional vomiting least 12 week ( need consecutive ) precede 12 month , history cyclic vomit least 3 episode previous 12 month . 3 . Female patient must negative serum urine pregnancy test postpartum least one year breast feed initial screen visit throughout study . For female patient able bear child , acceptable method birth control must use throughout study . Patients unable bear child must documentation case report form ( i.e. , tubal ligation , hysterectomy , postmenopausal [ define minimum one year since last menstrual period ] ) . 4 . Able provide voluntary , write informed consent full comprehension aspect protocol . 1 . Serious underlying disease ( cardiovascular , genitourinary , urinary , thyroid hematological disease , psychiatric disorder , central nervous system disorder , coagulation disorder ) . 2 . Clinically significant abnormal examination finding laboratory test . 3 . Inability stop take certain medication , plan change medication ( include herbal remedy ) would interfere study assessment . 4 . Use drug ethanol may interfere compliance study procedure influence study outcome . 5 . Presence medical condition could interfere interpretation study data . 6 . Significant use nicotine caffeine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Chronic Functional Vomiting</keyword>
	<keyword>Functional Vomiting</keyword>
	<keyword>Cyclic Vomiting</keyword>
</DOC>